Oxycodone PR or high dose levodopa not effective against parkinsonian central pain, suggests study
A new study published in the journal of Movement Disorders found that neither oxycodone-prolonged release (PR) nor higher doses of levodopa/benserazide offer significant relief for Parkinsonian central pain (PCP).
Patients with Parkinson's disease (PD) report chronic pain which has a significant negative influence on their quality of life unlike the general population. The patients with Parkinson's disease experience a wide range of chronic pain. This includes non-specific pain like musculoskeletal, radicular and restless syndrome and specific pain like dystonia and parkinsonian central pain (PCP), also known as 'central neuropathic pain'. These pains are mostly caused by various underlying neuropathic, nociceptive and nociplastic mechanisms.
The OXYDOPA study evaluated the pain-relieving effects of oxycodone-PR and increased doses of levodopa/benserazide in patients with PCP. The trial was conducted across 15 centers within the French NS-Park network and included a meticulous design to ensure reliable outcomes. This randomized, double-blind, double-dummy, placebo-controlled, multicenter parallel-group trial ensured that any changes in pain were due to the treatment rather than psychological factors.
The study included a total of 66 PD patients who reported significant PCP (measured as ≥30 on the Visual Analogue Scale) were randomly assigned to receive either oxycodone-PR (up to 40 mg/day), levodopa/benserazide (up to 200 mg/day) or a matching placebo. This was administered three times daily and these treatments were added to the existing dopaminergic therapy which is the standard treatment for PD.
The major findings of this study were:
After 10 weeks, the primary endpoint was the change in average pain intensity over the previous week, rated on the VAS. The mean change in pain intensity for the oxycodone-PR group was a decrease of 17 points (±18.5), the levodopa/benserazide group saw a decrease of 8.3 points (±11.1) and the placebo group experienced a decrease of 14.3 points (±18.9). When compared to the placebo, the difference was negligible for both treatments. Oxycodone-PR showed an absolute difference of -1.54 points, while levodopa/benserazide showed a difference of +7.79 points
All-cause adverse events were experienced by a comparable percentage of participants in each group. Oxycodone-PR was associated with the highest rate of trial dropout (39%) when compared to levodopa/benserazide (5%) and placebo (15%). In summary, despite low tolerance of oxycodone-PR, the findings of this study was unable to derive if this was better for PCP patients than a higher dosage of levodopa.
Reference:
Brefel‐Courbon, C., Harroch, E., Marques, A., Devos, D., Thalamas, C., Rousseau, V., Ory‐Magne, F., Fabbri, M., Maltête, D., Rouaud, T., Drapier, S., Tir, M., Thobois, S., Salhi, H., Corvol, J. C., Castelnovo, G., Lagha‐Boukbiza, O., Fluchère, F., Frismand, S., … Rascol, O. (2024). Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial. In Movement Disorders. Wiley. https://doi.org/10.1002/mds.29878
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.